108 results on '"Emmanuel Gabriel"'
Search Results
2. Disparities in Time to Treatment for Breast Cancer
- Author
-
Kulkaew, Sukniam, Ali Abbaszadeh, Kasbi, Mohammed Ali, Ashary, Kyle, Popp, Kristopher, Attwood, Anthony, George, and Emmanuel, Gabriel
- Subjects
Cancer Research ,Oncology ,Humans ,Black People ,Female ,Breast Neoplasms ,Breast ,Hispanic or Latino ,General Medicine ,Time-to-Treatment - Abstract
This study aimed to identify the demographic/socioeconomic factors associated with disparities in time to breast cancer treatment.We conducted an analysis of breast cancer patients from the National Cancer Database, 2008-2019. Time intervals from diagnosis to surgery, radiation, and chemotherapy were compared based on age, sex, race, and socioeconomic status.A total of 715,210 patients with breast cancer were included. Overall, Hispanic patients had the longest times to surgery, radiation, and chemotherapy compared to non-Hispanic patients (surgery 73.3 vs. 53.8 days, radiation 177.2 vs. 136.9 days, chemotherapy 83.0 vs. 66.5 days, all p0.01). Similarly, black patients, those who were uninsured, and those with lower income ($63,000) had the longest times to treatment.We identified several racial/socioeconomic disparities in time to treatment. Further investigation into the causes of these disparities is of increasing importance to address inequities in breast cancer care.
- Published
- 2022
- Full Text
- View/download PDF
3. Antioxidant potentials of the pod extract of Caesalpinia pulcherrima Swartz (Fabeace) and the theoretical evaluation of the antioxidant property of the isolated compounds
- Author
-
null Kolade Olatubosun FALOYE, null Samson Oluwaseyi FAMUYIWA, null Kemi Feyisayo AKINWUNMI, null Charlotte Mungho. TATA, null Marcus Durojaiye AYOOLA, null Emmanuel Gabriel FAKOLA, null Olawale Folorunso AKINYELE, and null Derek Tantoh NDINTEH
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Abstract
Various diseases associated with oxidative stress have necessitated the need to investigate plants for antioxidant agents. This study aims to investigate the antioxidant potential of the extract and fractions of C. pulcherrima and estimate the quantum chemical properties of polyphenolic compounds isolated from its most active antioxidant fraction. Methanolic extract and partition fractions of the pods of the plant were assayed for their antioxidant activity using four models: 1,1-diphenyl-2-dipicrylhydrazyl radical scavenging, ferric reducing antioxidant power, total antioxidant capacity and hydroxyl radical scavenging activity. Total phenolic and flavonoid contents of the extract and fractions were also investigated. Furthermore, the quantum chemical properties of two polyphenolic compounds were calculated to predict the antioxidant potential. The extract exhibited good antioxidant activity with IC50 = 45.63 µg/ml comparable to ascorbic acid of IC50 = 37.94 µg/ml, high reducing power with value at 376.74 ± 6.78, total antioxidant capacity obtained at ascorbic acid equivalence of 383 ± 8.16 mgAAE/g and potent hydroxyl radical scavenging activity with value at 580.97 µg/ml with ascorbic acid at 30.7 µg/ml. The total phenol and flavonoid contents values at 540.53 ± 3.71 and 347.87 ± 7.13 respectively. Furthermore, the results obtained from the quantum chemical calculations reveals polyphenolic compounds; 5(4-hydroxyphenyl)-3-hydroxy-2-methoxyphenol and 3(4-methanetriiol-2,6-dihydroxyphenoxy)-3’, 4’, 5’, 5, 7-pentahydroxy flavonol as promising antioxidant agents. The study concluded that C. pulcherrima pods have good antioxidant activity. Also, the polyphenolic compounds are among the chemical constituents responsible for the antioxidant activity obtained for the extract and ethyl acetate fraction.
- Published
- 2022
- Full Text
- View/download PDF
4. Immunotherapies in rare cancers
- Author
-
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, Mohammed Ali Ashary, Mizba Baksh, and Emmanuel Gabriel
- Subjects
Cancer Research ,Oncology ,Molecular Medicine - Abstract
Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers that individually occur at extremely low frequencies. In the United States (US), their frequency is approximately 15 cases per 100,000 people, and it is even lower in Europe with approximately 6 cases per 100,000 people. However, combined their frequency of occurrence is much higher than any singular cancer. Cancer treatment and management has tremendously improved in the last decade, particularly with the administration of immune-based therapies. The four most prevalent immune-based therapies are (1) the use of immune-checkpoint inhibitors, (2) macrophage therapy, (3) Chimeric Antigen Receptor (CAR) T cell therapy, and (4) neoantigen-based therapies. In our review, we discuss these various aproaches and their implementation in the treatment of a variety of rare cancers. Furthermore, we discuss their limitations and potential strategies to overcome them to enhance the therapeutic efficacy of these approaches. Finally, our article presents the future directions and other additional immune therapies that may be incorporated into the treatment of rare cancers.
- Published
- 2023
- Full Text
- View/download PDF
5. APPRAISAL OF CONDITIONAL ATTRIBUTES OF RESIDENTIAL BUILDINGS IN AKURE, NIGERIA
- Author
-
Solomon Oisasoje Ayo-Odifiri and Emmanuel Gabriel
- Subjects
Geography ,Housing tenure ,State government ,Urban infrastructure ,Toilet Facility ,Enforcement ,Agricultural economics - Abstract
The situation of residential buildings in urban areas must be assessed to ascertain their form and age, functions, convenience, and liveability. As a result, this paper evaluates selected aspects of the condition of residential buildings in Akure, Nigeria. The study's objectives include examining the types of housing units, plot coverage, the number of rooms, and building setbacks. Other factors include housing tenure, the condition of the in-house tap, the type of toilet facilities, and the age of the buildings. The study drew on both primary and secondary data sources. A total of 1,369 people were polled, with 684, 480, and 205 representing the core, transition, and peripheral zones. According to the findings, tenement buildings accounted for 62.3 percent of Akure's residential buildings. In the city core, 88.6 percent of the respondents developed their lands above 50 percent, while 20.0 percent developed their lands above 50 percent on the outskirts. The paper suggests that the relevant stakeholders should enforce the subsisting building regulations, introduce environmental inspectors and mobile courts, and the Ondo State government should invest in urban infrastructure.
- Published
- 2021
- Full Text
- View/download PDF
6. Prognostic models for stage I–III esophageal cancer: a comparison between existing calculators
- Author
-
Denslow A Trumbull, Enrique F. Elli, Riccardo Lemini, Dorin T. Colibaseanu, Kristopher Attwood, Emmanuel Gabriel, Aaron Spaulding, Moshim Kukar, and Tamara Díaz Vico
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,External validation ,Cancer ,Esophageal cancer ,Nomogram ,medicine.disease ,law.invention ,Calculator ,law ,Internal medicine ,medicine ,Overall survival ,Original Article ,business ,Predictive modelling ,Prognostic models - Abstract
Background Determining the best approach for esophageal cancer and predicting accurate prognosis are critical. Multiple studies evaluated characteristics associated with overall survival, and several prediction models have been developed. This study aimed to evaluate existing models and perform external validation of selected models. Methods A retrospective investigation of a multi-site institutional enterprise for patients with a diagnosis of esophageal cancer between 2013-2014 was performed. Selected survival prediction models included the Roswell Park Comprehensive Cancer Center (RPCCC) calculator, Oregon Health & Science University (OHSU) calculator, and two nomograms published by Shapiro et al. and Sun et al. One-year overall survival, level of agreement, and performance for each model were evaluated. Results A total of 104 patients were included and used to assess the prediction models. One-year overall survival was 0.76. Different calculators tended to rank patients similarly; however, they did not agree on predicted overall survival. The least disparity in correlation was observed between OHSU and Shapiro calculators. Shapiro's model achieved the highest performance [area under the curve (AUC) =0.63]. Conclusions Selected models showed fair results in estimating individual overall survival, although none achieved a high performance. While these tools may support the decision-making process for esophageal cancer patients, their implementation in clinical practice requires improved refinement to optimize their clinical utility.
- Published
- 2021
- Full Text
- View/download PDF
7. Outcomes of patients with invasive mucinous and tubular carcinomas of the breast
- Author
-
Emmanuel Gabriel, Subhasis Misra, Kai Huang, and Sanjay P. Bagaria
- Subjects
Oncology ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,Breast Neoplasms ,Disease ,Adenocarcinoma ,Breast cancer ,Internal medicine ,Internal Medicine ,medicine ,Adjuvant therapy ,Humans ,Mucinous carcinoma ,Breast ,Stage (cooking) ,Aged ,business.industry ,Cancer ,Prognosis ,medicine.disease ,Adenocarcinoma, Mucinous ,Chemotherapy, Adjuvant ,Female ,Surgery ,business ,Adjuvant - Abstract
Invasive tubular carcinoma (ITC) and invasive mucinous carcinoma (IMC) of the breast are rare histologic subtypes of breast cancer associated with favorable prognoses. The aim of our study was to investigate the outcomes for these rare subtypes using the National Cancer Database. Female patients diagnosed with ITC or IMC between 2005 and 2014 were analyzed. The primary outcome was overall survival (OS), and we analyzed its association with adjuvant therapy. 2735 patients with ITC and 5602 patients with IMC were identified. ITC presented in younger patients (57 vs. 67 years), had smaller tumors (size
- Published
- 2021
- Full Text
- View/download PDF
8. Clinicopathologic Characteristics and Prognosis of Invasive Papillary Carcinoma of the Breast
- Author
-
Lara Appiah, M Emmanuel Gabriel, Ankita Mishra, Sanjay P. Bagaria, Subhasis Misra, and Kai Huang
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Breast Neoplasms ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,parasitic diseases ,medicine ,Recurrent disease ,Overall survival ,Humans ,Breast ,cardiovascular diseases ,Stage (cooking) ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Carcinoma, Ductal, Breast ,Middle Aged ,Prognosis ,Invasive ductal carcinoma ,Carcinoma, Papillary ,United States ,030220 oncology & carcinogenesis ,Invasive Papillary Breast Carcinoma ,Female ,030211 gastroenterology & hepatology ,Surgery ,Papillary carcinoma ,business - Abstract
Background Invasive papillary carcinoma (IPC) of the breast is thought to carry a more favorable prognosis than invasive ductal carcinoma (IDC). The aim of this study is to investigate the clinicopathological characteristics between IPC and IDC and their prognosis using a large nationwide data set. Methods Female patients diagnosed with malignant IPC and IDC between 2005 and 2014 were analyzed. Patients with incomplete survival data, stage 0/IV, unknown stage, or recurrent disease were excluded. Five-year overall survival was compared between IPC and IDC. Results Among 308,426 patients, 1147 had IPC and 307,279 had IDC. IPC presented more in older postmenopausal women, black Americans, and people who had government insurance. IPC had larger tumor size, lower-grade, and earlier-stage disease, less node-positive disease, higher hormone positivity, and lower human epidermal growth factor receptor 2 amplification. Adjuvant radiation and chemotherapy rates were lower in IPC than those in IDC. IPC had a similar 5-year overall survival as compared with IDC overall (86.8% versus 88.7%) (P = 0.06). Age, pathologic stage, and radiation treatment were shown to be independent prognostic factors of IPC. Conclusions IPC has a similar prognosis as IDC, suggesting that these patients should follow the same treatment protocols.
- Published
- 2021
- Full Text
- View/download PDF
9. Inflammatory Pseudotumor Resembling a Malignant Pancreatic Disease Process
- Author
-
Mira Shoukry, Jamie Kaplan, Catherine Mangum, and Emmanuel Gabriel
- Subjects
Cancer Research ,Abdominal pain ,Pathology ,medicine.medical_specialty ,Pancreatic disease ,Malignancy ,Granuloma, Plasma Cell ,Diagnosis, Differential ,Fibrosis ,Pancreatic cancer ,medicine ,Humans ,Aged ,business.industry ,Pancreatic Diseases ,General Medicine ,medicine.disease ,Pancreatic Neoplasms ,Cell Transformation, Neoplastic ,Oncology ,Inflammatory pseudotumor ,Immunohistochemistry ,Female ,medicine.symptom ,Differential diagnosis ,business - Abstract
Background/aim Inflammatory pseudotumors are complex entities given that they carry varying characteristics with a multitude of behaviors that can resemble a malignancy clinically, radiographically, and histologically. Patients and methods Our case report presents a 65-year-old-female with a history of fever, abdominal pain, and anemia with imaging suggestive of a malignant disease process involving an ill-defined soft tissue mass between the left adrenal gland and pancreatic tail. Results Following diagnostic laparoscopy with abdominal washings and subsequent open resection of the mass, final pathology revealed multiple specimens demonstrating dense fibrosis with admixed spindled cells and inflammatory cells, an overarching morphology, and an immunohistochemical staining profile consistent with pancreatic inflammatory pseudotumor. Conclusion Inflammatory pseudotumor is a challenging diagnosis and should be included in the differential diagnosis for a patient who presents with nonspecific symptoms and an ill-defined mass on imaging.
- Published
- 2021
- Full Text
- View/download PDF
10. Experimental and Numerical Investigation of Effect of Inclination on sCO2 Heat Transfer in a Circular Pipe
- Author
-
Emmanuel Gabriel-Ohanu, Alok Shah, Akshay Khadse, Erik Fernandez, and Jayanta S. Kapat
- Abstract
Supercritical carbon dioxide (sCO2) can be utilized as a working fluid in various thermal systems including large scale power cycles; portable power production units, centralized coolant systems and standalone cooling devices. However,the lack of accurate prediction tools such as heat transfer coefficient correlations, and insufficient research studies about the mechanisms controlling heat transfer processes, are hindering its practical realization for key energy and cooling systems. The overall objective of this study is to extend fundamental knowledge about heat transfer and fluid dynamic processes in conduits pertinent to sCO2 with an emphasis on flow inclination and directional effects. This paper present the a study on effects of gravity, buoyancy on sCO2 flow at temperature near and away from the pseudocritical temperature. The experimental setup consists of a high temperature and pressure sCO2 heat transfer loop and flow testing facility. Recently researched sCO2 heat exchangers can have tubes oriented at different angles such as 45° or 90° to horizontal. For optimized design of efficient and cost-effective turbo-machinery components utilizing sCO2 as the heat transfer fluid, an understanding of convective heat transfer inside a tube/pipe is equally as important as external heat transfer. This paper presents an experimental and numerical study on sCO2 heat transfer at various inclinations with angles ranging from 0° (horizontal) to 90° (vertical) along with upward and downward flow direction with different inlet temperature. Thermocouple based temperature measurement is utilized at multiple locations within the test section axially and circumferentially to study the temperature distributions on the tube surface. Computational Fluid dynamics (CFD) simulations have been performed using ANSYS Fluent to complement experimental data. The CFD and experiment have been analysed against known Gnielinski nusselt number correlation.
- Published
- 2022
- Full Text
- View/download PDF
11. Gastric Cancer Disparities Among Asian American Subpopulations
- Author
-
Emmanuel Gabriel, Riccardo Lemini, Kristopher Attwood, Denslow A Trumbull, and Moshim Kukar
- Subjects
Male ,Cancer Research ,Future studies ,Esophageal Neoplasms ,Population ,Esophageal adenocarcinoma ,Adenocarcinoma ,White People ,Stomach Neoplasms ,Asian americans ,medicine ,Humans ,education ,Aged ,Data Management ,Aged, 80 and over ,education.field_of_study ,Asian ,business.industry ,Significant difference ,Cancer ,Health Status Disparities ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Oncology ,Population Surveillance ,Cohort ,Cancer disparities ,Female ,business ,Demography - Abstract
BACKGROUND/AIM Asian Americans (AA) are one of the largest and fastest growing minority groups in the United States consisting of 18 million people. This population is an ethnically diverse group that tends to be classified as one cohort resulting in hidden survival disparities among AA subgroups. PATIENTS AND METHODS The National Cancer Data Base was queried for patients of Korean, Japanese or Filipino ancestry with gastric adenocarcinoma or esophageal adenocarcinoma between 2004 and 2013. RESULTS A total of 28,213 patients met the inclusion criteria: 1,542 with gastric adenocarcinoma and 26,671 with esophageal adenocarcinoma. The Korean group with gastric cancer (0.42) showed improved 5-year survival over the Japanese (0.31) and Filipino (0.21; p
- Published
- 2020
- Full Text
- View/download PDF
12. Age-Based Trends of Gastric Adenocarcinoma in the United States
- Author
-
Enrique F. Elli, Kristopher Attwood, Sanjay P. Bagaria, Denslow A Trumbull, Emmanuel Gabriel, and Riccardo Lemini
- Subjects
Adult ,Male ,Latin Americans ,Databases, Factual ,Adolescent ,Adenocarcinoma ,Gastric adenocarcinoma ,Young Adult ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Stomach Neoplasms ,medicine ,Humans ,Young adult ,Neoplasm Staging ,Aged ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Incidence ,Age Factors ,Cancer ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,United States ,030220 oncology & carcinogenesis ,Age distribution ,Female ,030211 gastroenterology & hepatology ,business ,Demography - Abstract
Background Recent studies have shown an increase in the incidence of gastric cancer (GC) among young adults in Asia and Latin America. However, it is unknown if a similar trend is happening in the United States. Methods A retrospective review of the National Cancer Database was conducted to identify patients diagnosed with gastric adenocarcinoma between the years of 2004 and 2013. Results A total of 93 734 patients were included. The two age groups below 40 did not see a change in GC incidence; however, age groups above 40 had increasing incidence. Patients aged 18 to 25 had the largest proportion of stage 4 disease and a poor survival (median 11.5 months), compared to older patients. Conclusion Despite the increasing trend of GC among individuals, the incidence of GC among young adults is not increasing. However, this subpopulation presents at more advanced stages (clinical stage 4) and thus has worse survival.
- Published
- 2020
- Full Text
- View/download PDF
13. Residual Tumor on Wide Excisional Margins After Treatment of Invasive Melanoma
- Author
-
Maria T Huayllani, Andrea Sisti, Antonio J. Forte, Brian D. Rinker, Jordan J. Cochuyt, Sanjay P. Bagaria, Aaron Spaulding, Emmanuel Gabriel, Daniel Boczar, and David J. Restrepo
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Multivariate analysis ,Comorbidity ,Residual ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,In patient ,Head and neck ,Melanoma ,Aged ,Aged, 80 and over ,business.industry ,Margins of Excision ,Cancer ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,Oncology ,030220 oncology & carcinogenesis ,Female ,Radiology ,Invasive Melanoma ,Neoplasm Recurrence, Local ,business ,After treatment - Abstract
BACKGROUND/AIM The surgical management of invasive melanoma has been debated for many years and recommended excisional margins have been established. We aimed to describe the factors and survival related to the presence of residual tumor in patients with invasive melanoma lymph nodes negative. PATIENTS AND METHODS We performed a retrospective study by querying the National Cancer Database from 2004 to 2015. Associations were tested using a multivariate analysis. Overall survival was compared using the Kaplan-Meier method. RESULTS A total of 26,440 patients met the inclusion criteria. For Breslow depth groups ≤1 mm and >2 mm, older age and location in the head and neck were factors associated to residual tumor in margins (p
- Published
- 2020
- Full Text
- View/download PDF
14. Assessment of Passive Architectural Strategies for Natural Ventilation in Libraries within Hot- Humid Climate
- Author
-
Thomas Terna Aule, Yaik Wah Lim, Pau Chung Leng, Kole Emmanuel Gabriel, and Moses Iorakaa Ayoosu
- Subjects
Climatology ,021105 building & construction ,0211 other engineering and technologies ,Environmental science ,Window (computing) ,Natural ventilation ,021108 energy ,02 engineering and technology ,Humid climate - Abstract
In buildings, natural ventilation is for human comfort; for odour removal, body and the structure cooling. A previous study revealed that libraries in Nigeria could not function efficiently without artificial ventilation and lighting. Artificial ventilation, aside from economic disadvantages, it is not reliable and anti-sustainability while natural ventilation is reliable, consume less energy, and in other words, it is more efficient when compared with other types of ventilation. The research evaluates the application of passive architectural strategies for natural ventilation in libraries within the hot-humid climate of Nigeria, intending to recommend natural ventilation strategies in libraries. Ten (10) libraries were selected randomly in the study area from both institutional and public libraries. The research conducted using observation schedule, the variables in the research are; Window types, Clerestory windows availability, Door openings, Screen walls, Courtyard, Other openings, use of external shading devices and orientation of the library. The data analysed using descriptive statistic; the results presented using tables, bar charts and pie charts. The research revealed that 29% of the cases studied use external vertical structural shading devices, 36% use horizontal shading devices, 21% use both vertical and horizontal shading devices to deflect solar radiation and 14% do not use any external shading devices. 80% of the libraries studied was oriented toward north-south (NS) direction, while 20% oriented toward east-west (EW) direction. Therefore, the majority of the libraries studied have desired orientation; however, each lacks one of the passive cooling strategies. Adequate natural ventilation in the libraries is achievable by the proper synthesis of the building orientation, proper design of building internal spaces, the proper position of window openings and use of projected window as well as clearstory. More so, further study to enhance natural ventilation configuration for the study area is desirable.
- Published
- 2020
- Full Text
- View/download PDF
15. Trends in utilization of sentinel node biopsy and adjuvant radiation in women ≥ 70
- Author
-
Tamanie E. Yeager, Sanjay P. Bagaria, Kristin Partain, Jinny Gunn, Riccardo Lemini, Sarah A. McLaughlin, Emmanuel Gabriel, Kristopher Attwood, and Tariq Almerey
- Subjects
medicine.medical_specialty ,Sentinel lymph node ,Breast Neoplasms ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Biopsy ,Internal Medicine ,medicine ,Humans ,Stage (cooking) ,Aged ,Neoplasm Staging ,Adjuvant radiotherapy ,medicine.diagnostic_test ,Sentinel Lymph Node Biopsy ,business.industry ,Cancer ,Sentinel node ,medicine.disease ,Oncology ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Axilla ,Lymph Node Excision ,Female ,Surgery ,Lymph Nodes ,Radiology ,business ,Axillary staging - Abstract
Background and objectives Omission of routine axillary staging and adjuvant radiation (XRT) in women ≥ 70 years old with early stage, hormone receptor-positive, clinically node-negative breast cancer has been endorsed based on several landmark studies. We sought to determine how much omission of axillary staging/XRT has been adopted. Methods Using the National Cancer Data Base, we selected malignant breast cancer cases in women ≥ 70 with ER + tumors, ≤2 cm with clinically negative lymph nodes who underwent breast conservation and had known XRT status in 2005-2015. The use of sentinel lymph node biopsy (SNB) and XRT status was summarized by year to determine trends over time. Results In total, 57 230/69 982 patients underwent SNB. Of the 12 752 patients in whom SNB was omitted, 6296 were treated at comprehensive community cancer programs. Regarding XRT, 33 891/70 114 received adjuvant XRT. There were no significant trends with regards to patients receiving SNB or those receiving XRT. Conclusion Since 2005, there has been no change in SNB or XRT for early stage ER + breast tumors. However, there was a difference in omission of SNB based on facility type and setting. Future monitoring is needed to determine if these trends persist following the recently released Choosing Wisely® recommendations.
- Published
- 2020
- Full Text
- View/download PDF
16. How Well Does Non-mass Enhancement Correlate With DCIS/Invasive Cancer?
- Author
-
Kai Huang, Maria Dufresne, Mizba Baksh, Samuel Nussbaum, Ali Abbaszadeh Kasbi, Ashary Mohammed, Pooja Advani, Andrey Morozov, Sanjay Bagaria, Sarah McLaughlin, and Emmanuel Gabriel
- Subjects
General Medicine - Abstract
Introduction Contiguous non-mass enhancement (NME) often coexists with a solid tumor component on MRI, but it can be challenging to predict whether NME represents invasive breast cancer, ductal carcinoma in situ (DCIS), benign disease, or biopsy site reaction. The purpose of this study was to determine the association between the size/extent of NME and the presence of invasive cancer and/or DCIS on final pathology. Methods This was a single institution retrospective analysis of a prospectively maintained breast cancer registry (2010-2020). Female patients who underwent surgical resection were included if they had a diagnosis of invasive breast cancer (with or without DCIS) and had an MRI showing both a solid mass and contiguous NME. The size of NME on MRI was compared with the size of invasive cancer and/or DCIS on the final pathology. Results From a total of 3443 patients, 225 patients were included. 86.2% had invasive ductal carcinoma (IDC), and 12.0% had invasive lobular carcinoma 76.9% were ER+, 16.4% were HER2+, and 13.3% were triple negative breast cancer (TNBC). 18.7% received neoadjuvant chemotherapy (NCT) of whom 31% achieved a complete radiographic/pathologic response. Pearson correlation coefficients (r) between the size of NME and invasive cancer/DCIS showed a strong and positive correlation of MRI NME with DCIS on pathology in patients without NCT. Subgroup analysis showed the strongest correlations for NME and DCIS among non-white (r = .70) and HER2 + patients (r = .74) who did not receive NCT. Conclusions Strong correlations between NME and DCIS were found for HER2 + disease and non-white patients, but only modest correlations were found for other patient/disease characteristics. These correlations may impact decisions in surgical approach.
- Published
- 2023
- Full Text
- View/download PDF
17. Abscopal Effect Following Cryoablation in a Patient with Metastatic Breast Cancer
- Author
-
Emmanuel Gabriel, Saranya Chumsri, Ismail Turker, and Jamie L. Kaplan
- Subjects
General Immunology and Microbiology ,General Biochemistry, Genetics and Molecular Biology - Published
- 2023
- Full Text
- View/download PDF
18. Age-related Survival Outcomes for Pancreatic Cancer by Age
- Author
-
ALI ABBASZADEH KASBI, MOHAMMED ALI ASHARY, MIZBA BAKSH, SAMUEL NUSSBAUM, KRISTOPHER ATTWOOD, and EMMANUEL GABRIEL
- Subjects
Research Article - Abstract
Background/Aim: Pancreatic cancer has a very poor prognosis, though outcomes based on age are not well characterized. The aim of current study was to analyze the survival of patients with pancreatic cancer based on age. Patients and Methods: Using National Cancer Data Base (NCDB), we determined survival outcome based on age among patients with pancreatic cancer. Results: A total of 423,482 patients between 2004 and 2017 were included in the study. Patients aged between 18 and 40-years-old had the worst 3-year survival rate among stage 1 disease. Conversely, patients over 65-years-old had the worst 3-year survival rate and presented with more advanced disease (clinical stages 3 and 4). Conclusion: Older patients with more advanced disease had worse survival.
- Published
- 2021
19. Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group
- Author
-
Sanjay P. Bagaria, Carol Swallow, Harini Suraweera, Chandrajit P. Raut, Mark Fairweather, Ferdinando Cananzi, Vittorio Quagliuolo, Giovanni Grignani, Daphne Hompes, Samuel J. Ford, Carolyn Nessim, Sameer Apte, Jacek Skoczylas, Piotr Rutkowski, Sylvie Bonvalot, Dimitri Tzanis, Emmanuel Gabriel, Elisabetta Pennacchioli, Markus Albertsmeier, Robert J. Canter, Raphael Pollock, Valerie Grignol, Kenneth Cardona, Adriana C. Gamboa, Marko Novak, Eberhard Stoeckle, Martin Almquist, Nita Ahuja, Nicholas Klemen, Winan Van Houdt, David Gyorki, Alexandra Gangi, Marco Rastrelli, Jos van der Hage, Yvonne Schrage, Sergio Valeri, Lorenzo Conti, Matthew R. Spiegel, Zhou Li, Marco Fiore, and Alessandro Gronchi
- Subjects
Oncology ,Surgery - Published
- 2022
- Full Text
- View/download PDF
20. National Analysis of Patients With External Ear Melanoma in the United States
- Author
-
Maria T Huayllani, Daniel Boczar, Sanjay P. Bagaria, Jeremie D. Oliver, Emmanuel Gabriel, Brian Rinker, Aaron Spaulding, Andrea Sisti, Antonio J. Forte, and David J. Restrepo
- Subjects
Male ,medicine.medical_specialty ,Medicare ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Statistical significance ,Tumor stage ,medicine ,Humans ,Ear, External ,030223 otorhinolaryngology ,Head and neck ,Melanoma ,Ear Neoplasms ,Aged ,business.industry ,Confounding ,030206 dentistry ,General Medicine ,Odds ratio ,medicine.disease ,United States ,Independent factor ,Otorhinolaryngology ,Female ,Surgery ,business - Abstract
BACKGROUND External ear melanoma (EEM) is a rare condition with controversies in the literature. We analyzed patients with EEM in the United States compared to other head and neck melanomas (OHNMs). METHODS The National Cancer Database (NCDB) was used to select patients with head and neck melanoma from January 1, 2004 to December 31, 2015. Mann-Whitney and χ tests were used to estimate statistical significance, and multivariate logistic regression to identify independent associations adjusted for confounders. RESULTS A total of 137,233 patients met the study criteria. Among them, 16,991 (12.4%) had EEM and 120,242 (87.6%) had OHNM. For patients with EEM, the mean (standard deviation) age was 66.26 (15.798) years. Most of the patients with EEM were men (85.5%), insured by Medicare (52.4%), and treated in Academic/Research Programs (47.7%) or Comprehensive Community Cancer Programs (32.3%). Most of the EEM tumors had invasive behavior (68.0%) were Stages 0 (30.3%) or I (40.3%), and were without ulceration (76.9%). Mean time to receive any treatment was 14.1 days for EEM compared with 14.6 days for OHNM (P
- Published
- 2019
- Full Text
- View/download PDF
21. Eyelid Melanoma in the United States
- Author
-
David J. Restrepo, Sanjay P. Bagaria, Maria T Huayllani, Emmanuel Gabriel, Andrea Sisti, Jeremie D. Oliver, Daniel Boczar, Brian Rinker, Aaron Spaulding, and Antonio J. Forte
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,Databases, Factual ,Database analysis ,Time to treatment ,Autopsy ,Medicare ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Stage (cooking) ,030223 otorhinolaryngology ,Melanoma ,Aged ,Aged, 80 and over ,business.industry ,Cancer ,030206 dentistry ,General Medicine ,Odds ratio ,Middle Aged ,Prognosis ,medicine.disease ,United States ,Otorhinolaryngology ,Female ,Surgery ,Eyelid Melanoma ,business - Abstract
BACKGROUND Eyelid melanoma (EM) is a rare condition that accounts for
- Published
- 2019
- Full Text
- View/download PDF
22. Experimental and computational studies of microwave-assisted watermelon rind – styrene based molecular imprinted polymer for the removal of malachite green from aqueous solution
- Author
-
Kehinde Nurudeen Awokoya, Vincent Olukayode Oninla, Gbadebo Clement Adeyinka, Marvellous Oladayo Ajadi, Omeke Tobias Chidimma, Emmanuel Gabriel Fakola, and Olawale Folorunso Akinyele
- Subjects
Multidisciplinary - Published
- 2022
- Full Text
- View/download PDF
23. 115. Novel Regional Approaches to In-transit Melanoma: Two-pronged Approach for Maximal Drug Efficacy
- Author
-
Jamie L. Kaplan, Antonio J. Forte, and Emmanuel Gabriel
- Subjects
Surgery - Published
- 2022
- Full Text
- View/download PDF
24. Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
- Author
-
Pei, Zhang, Xiaobin, Hou, Boning, Cai, Wei, Yu, Jing, Chen, Xiang, Huang, Ye, Li, Mingyue, Zeng, Zhipeng, Ren, Emmanuel, Gabriel, Baolin, Qu, and Fang, Liu
- Subjects
Original Article ,General Medicine - Abstract
BACKGROUND: Treatments for patients with advanced esophageal cancer are still limited. Pembrolizumab has demonstrated antitumor activity in patients with advanced esophageal cancer in previous studies. Few studies have assessed safety and efficacy in routine clinical practice. We investigated the real-world outcomes of pembrolizumab for patients with advanced esophageal cancer. METHODS: This retrospective, observational study collected 57 advanced esophageal squamous cell carcinoma (ESCC) patients from October 1, 2019 to October 1, 2021, 57 who received different patterns of treatments according to the staging were collected. Briefly, patients diagnosed with locally advanced and surgically resectable ESCC received neoadjuvant therapy followed by surgery. For patients with locally advanced, unresectable ESCC, the treatment regimen including chemoradiotherapy combined with pembrolizumab was performed. Patients with metastatic ESCC or those not suitable for radiotherapy received pembrolizumab plus chemotherapy. Safety was assessed in all treated patients. The objective response rate (ORR) was used to evaluate the efficacy. RESULTS: The ORR was 74.1% (40/54) among all patients. The most common adverse events (AEs) were leukopenia (36.8%, 21/57), nausea (28.1%, 16/57), and thrombocytopenia (14%, 8/57). Grade III and higher AEs were observed in 9 of the 57 patients (15.8%). CONCLUSIONS: For patients with advanced ESCC, combined treatment with pembrolizumab was effective and safe. Multicenter studies should be carried out for further confirmation.
- Published
- 2022
- Full Text
- View/download PDF
25. SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database
- Author
-
Adrienne Groman, Emmanuel Gabriel, Sarbajit Mukherjee, Moshim Kukar, Lei Deng, Stuthi Perimbeti, and C. Jiang
- Subjects
Oncology ,Gastric adenocarcinoma ,medicine.medical_specialty ,business.industry ,Internal medicine ,Preoperative chemotherapy ,Medicine ,Cancer ,Hematology ,Sensitivity (control systems) ,business ,medicine.disease - Published
- 2021
- Full Text
- View/download PDF
26. Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections
- Author
-
Elizabeth B. Habermann, Emmanuel Gabriel, Amit Merchea, Courtney N. Day, Riccardo Lemini, Iktej S. Jabbal, Osayande Osagiede, and Dorin T. Colibaseanu
- Subjects
medicine.medical_specialty ,Gastrointestinal tract ,business.industry ,Proportional hazards model ,Colorectal cancer ,Gastroenterology ,Neuroendocrine tumors ,medicine.disease ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Quartile ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,Original Article ,Stage (cooking) ,business ,Radical resection - Abstract
Background Colorectal neuroendocrine tumors (NETs) are the most common NETs of the gastrointestinal tract. Due to the rarity, colorectal NETs are understudied and are not clearly understood. Our study sought to identify the factors associated with worse outcomes for colorectal NETs following resection. Methods We identified patients diagnosed with colorectal NETs [2004-2014] who underwent resection from the National Cancer Data Base. Non-NETs were excluded. Overall survival (OS) was evaluated using the Kaplan Meier method. Cox proportional hazards and logistic regression models were used to assess factors associated with radical versus local resection, OS and LOS. Results A total of 7,967 colon and 11,929 rectal NETs were analyzed. The majority of colon (93.4%) and rectal (89.1%) NETs underwent radical and local resection respectively. The 5-year OS was 69% and 92% for colon and rectal NETs respectively. Older age (OR 1.45, CI 1.37-1.53) and clinical stage 4 (OR 9.91, CI 4.56-21.52) were associated with higher odds for colonic radical resection. Lowest median income quartile (OR 1.41, CI 1.21-1.64) and African Americans (OR 1.26, CI 1.07-1.49) experienced higher mortality for colon and rectal NETs respectively. Conclusions Racial minority and low-income patients experience worse outcomes for colorectal NETs following resection.
- Published
- 2020
27. Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma
- Author
-
Sanjay P. Bagaria, Yong Chen, Emmanuel Gabriel, Kai Huang, Subhasis Misra, Leigh L. Speicher, Nancy L. Dawson, Leila M. Tolaymat, and Riccardo Lemini
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,medicine.medical_treatment ,Sentinel lymph node ,Neuroendocrine tumors ,03 medical and health sciences ,0302 clinical medicine ,Biopsy ,medicine ,Humans ,Lymph node ,Melanoma ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Sentinel Lymph Node Biopsy ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Survival Rate ,Dissection ,medicine.anatomical_structure ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Lymph Node Excision ,030211 gastroenterology & hepatology ,Surgery ,Lymphadenectomy ,Female ,Radiology ,Sentinel Lymph Node ,business ,Follow-Up Studies - Abstract
Background Relatively few cutaneous head and neck melanoma (CHNM) patients with were included in the multicenter selective lymphadenectomy trial II (MSLT-II). Our objective was to investigate whether immediate completion lymph node dissection completion of lymph node dissection (CLND) was associated with survival benefit for sentinel lymph node (SLN) positive CHNM using the National Cancer Database. Methods SLN positive patients with CHNM from 2012 to 2014 were retrospectively analyzed. Patients were divided into two groups: those who underwent SLN biopsy (SLNB) only versus those who underwent SLNB followed by CLND (SLNB + CLND). The primary outcome was 5-year overall survival (OS). Results Among 530 SLNB + patients, 342 patients underwent SLNB followed by CLND (SLNB + CLND). The SLNB only group had fewer positive SLN, less advanced pathologic stage, and a lower rate of adjuvant immunotherapy. There was no significant difference in 5-year OS between the two groups (51.0% vs 67%; P = .56). After adjusting for pathologic stage, there remained no difference in 5-year OS among patients with stage IIIA (63.0% vs. 73.6%, P = 0.22) or IIIB/IIIC disease (39.1% vs 57.8%; P = .52). Conclusions Using a large nationwide database, CLND was not shown to be associated with improved OS for patients with SLNB positive CHNM, validating the results of MSLT-II.
- Published
- 2020
28. Advanced Tumor Imaging Approaches in Human Tumors
- Author
-
Samuel Nussbaum, Mira Shoukry, Mohammed Ali Ashary, Ali Abbaszadeh Kasbi, Mizba Baksh, and Emmanuel Gabriel
- Subjects
Cancer Research ,Oncology - Abstract
The management of cancer has always relied heavily on the imaging modalities used to detect and monitor it. While many of these modalities have been around for decades, the technology surrounding them is always improving, and much has been discovered in recent years about the nature of tumors because of this. There have been several areas that have aided those discoveries. The use of artificial intelligence has already helped immensely in the quality of images taken but has not yet been widely implemented in clinical settings. Molecular imaging has proven to be useful in diagnosing different types of cancers based on the specificity of the probes/contrast agents used. Intravital imaging has already uncovered new information regarding the heterogeneity of the tumor vasculature. These three areas have provided a lot of useful information for the diagnosis and treatment of cancer, but further research and development in human trials is necessary to allow these techniques to fully utilize the information obtained thus far.
- Published
- 2022
- Full Text
- View/download PDF
29. A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy
- Author
-
Yongkui, Yu, Wei, Wang, Zimin, Qin, Haomiao, Li, Qi, Liu, Haibo, Ma, Haibo, Sun, Thomas L, Bauer, Jose M, Pimiento, Emmanuel, Gabriel, Thomas, Birdas, Yin, Li, and Wenqun, Xing
- Subjects
Original Article ,General Medicine - Abstract
BACKGROUND: There are various treatment options for esophageal squamous cell cancer. including surgery, peri-operative chemotherapy, and radiation. More recently, neoadjuvant immunotherapy has also been shown improve outcomes. In this study, we addressed the question, “Can we predict which patients with esophageal squamous cell cancer will benefit from neoadjuvant immunotherapy?”. METHODS: All patients with thoracic esophageal squamous-cell carcinoma (T2N+M0-T3-4N0/+M0) (according to the eighth edition of the National Comprehensive Cancer Network guidelines) who underwent immune neoadjuvant immunochemotherapy with programmed cell death protein 1 (PD-1) combined with paclitaxel plus cisplatin or nedaplatin in the Affiliated Cancer Hospital of Zhengzhou University, China, between November 2019 and August 2021 were included in this study. All patients underwent surgical resection. We developed a response [tumor regression grade (TRG)] prediction model using the least absolute shrinkage and selection operator (LASSO) regression incorporating factors associated with response. The accuracy of the prediction model was then validated. RESULTS: We included 79 patients who underwent neoadjuvant immunotherapy combined with chemotherapy, aged 48–78 years (62.05±6.67), including 21 males and 58 females. There were five cases of immune-related pneumonia, of which three cases were diagnosed as immune-related pneumonia during the perioperative period, and one case of immune-related thyroid dysfunction changes. After LASSO regression, the factors that were independently associated with TRG were clinical T stage before neoadjuvant therapy, clinical N stage before neoadjuvant therapy, albumin level difference from before to after neoadjuvant therapy, white blood cell (WBC) count before neoadjuvant therapy, and T stage before surgery. We constructed a prediction model, plotted the nomogram, and verified its accuracy. Its Brier score was 0.13, its calibration slope was 0.98, and its C-index was 0.90 (95% CI: 0.82–0.97). CONCLUSIONS: Our prediction model can predict the likelihood of TRG in patients with esophageal squamous cell cancer after immunotherapy combined with neoadjuvant chemotherapy. Using this prediction model, we plan to conduct a subsequent neoadjuvant radiotherapy in patients with of TRG 2–3 patients with neoadjuvant radiotherapy.
- Published
- 2022
- Full Text
- View/download PDF
30. Intraoperative fluid restriction in hyperthermic intraperitoneal chemotherapy
- Author
-
Sanjay P. Bagaria, Tariq Almerey, Klaus D. Torp, and Emmanuel Gabriel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Fluid administration ,Continuous infusion ,Anastomosis ,Young Adult ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Intraoperative Care ,business.industry ,030208 emergency & critical care medicine ,Cytoreduction Surgical Procedures ,Hyperthermia, Induced ,Middle Aged ,Appendix ,Surgery ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Peritoneal Cancer Index ,Fluid Therapy ,Female ,Hyperthermic intraperitoneal chemotherapy ,Fluid restriction ,Packed red blood cells ,business - Abstract
Background Multiple studies highlight the importance of liberal fluid administration in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Over-resuscitation can delay recovery and wound healing. We report an intraoperative protocol that restricts fluid administration and minimizes morbidity. Materials and Methods Retrospective analysis of 35 patients that underwent CRS-HIPEC for curative intent under fluid restriction protocol from June 2015 to July 2017 was performed. Protocol consists of continuous infusion of vasopressin 0.02 units/h and maintaining urine output at 0.5 mL/kg/h via crystalloid and colloid. Endpoint was Clavien-Dindo ≥3 events within 30 d of CRS-HIPEC. Results Median age was 56 y; 71% were female. Malignancies treated: appendix (49%), colon (31%), and other (20%). Median peritoneal cancer index was 15, complete cytoreduction was achieved in 91% of patients. Median time for return of bowel function was 5 d, median length of hospital stay was 7 d. There were 28 bowel anastomoses. Median intraoperative crystalloid, colloid, and packed red blood cells were (1900, 1500, and 700 mL), respectively. Clavien-Dindo grade 3-4 events occurred in five patients. There were no deaths 30 d after surgery. Conclusions A fluid restriction protocol appears to be safe and feasible in the setting of CRS-HIPEC for curative intent.
- Published
- 2018
- Full Text
- View/download PDF
31. A novel anesthesiologist-led multidisciplinary model for evaluating high-risk surgical patients at a comprehensive cancer center
- Author
-
Richard D. Urman, Danna Al-Hadidi, Steven J. Nurkin, Raymond Sroka, Emmanuel Gabriel, and Timothy D. Quinn
- Subjects
Adult ,Male ,medicine.medical_specialty ,MEDLINE ,Guidelines as Topic ,Risk Assessment ,Perioperative Care ,03 medical and health sciences ,0302 clinical medicine ,030202 anesthesiology ,Multidisciplinary approach ,Neoplasms ,Diabetes mellitus ,medicine ,Humans ,Anesthesia ,Medical diagnosis ,Retrospective Studies ,business.industry ,General surgery ,Cancer ,Sleep apnea ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Anesthesiologists ,General Surgery ,030220 oncology & carcinogenesis ,Heart failure ,Female ,business - Abstract
The objective of this retrospective analysis was to describe the development and implementation of an anesthesiologist-led multidisciplinary committee to evaluate high-risk surgical patients in order to improve surgical appropriateness. The study was conducted in an anesthesia preoperative evaluation clinic at an academic comprehensive cancer center. One hundred sixty-seven high-risk surgical patients with cancer-related diagnoses were evaluated and discussed at a High-Risk Committee (HRC) meeting to determine surgical appropriateness and optimize perioperative care. The HRC is an anesthesiologist-led model for multidisciplinary review of high-risk patients developed at Roswell Park Comprehensive Cancer Center. The group of high-risk patients in which surgery was not performed had, on average, a greater percentage of hypertension, smoking history, dyspnea, heart failure, chronic obstructive pulmonary disease, diabetes, renal failure, and sleep apnea than the group in whom surgery was performed. Only one of 107 high-risk patients who had surgery died within the first 30 days after surgery. A smaller percentage of patients died in the group that had surgery versus the group in which surgery was canceled. For all patients discussed by the HRC, the mortality was less than 2% within the first 30 days after the HRC.
- Published
- 2018
- Full Text
- View/download PDF
32. Laparoscopic proximal gastrectomy for gastric neoplasms
- Author
-
Steven N. Hochwald, Kfir Ben-David, Moshim Kukar, and Emmanuel Gabriel
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Reflux ,General Medicine ,Perioperative ,030204 cardiovascular system & hematology ,Anastomosis ,medicine.disease ,Surgery ,03 medical and health sciences ,Dissection ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,medicine ,Adenocarcinoma ,Gastrectomy ,business ,Lymph node - Abstract
Background For cancers of the distal gastroesophageal junction or the proximal stomach, proximal gastrectomy can be performed. It is associated with several perioperative benefits compared with total gastrectomy. The use of laparoscopic proximal gastrectomy (LPG) has become an increasingly popular approach for select tumors. Methods We describe our method of LPG, including the preoperative work-up, illustrated depictions of the key steps of the surgery, and our postoperative pathway. Results A total of 6 patients underwent LPG between July, 2013 to June, 2017. Five patients had early-stage adenocarcinoma, and 1 patient had a gastrointestinal stromal tumor. The median age of the cohort was 70, and each patient had significant comorbidities. Conversion to open was required for 1 patient. All patients had negative final margins and an adequate lymph node dissection (median number of nodes examined was 15, range 12-22). The median postoperative length of stay was 7 days (range 4-7). Two patients developed anastomotic strictures requiring intervention, and 1 patient experienced significant reflux. At a median follow-up of 11 months, there was 1 recurrence. Three patients were alive without evidence of disease, and 2 patients died from other causes. Conclusions For carefully selected patients, LPG is a safe and reasonable alternative to total gastrectomy, which is associated with similar oncologic outcomes and low morbidity.
- Published
- 2018
- Full Text
- View/download PDF
33. Intravital microscopy in the study of the tumor microenvironment: from bench to human application
- Author
-
Joseph J. Skitzki, Emmanuel Gabriel, Daniel T. Fisher, Kazuaki Takabe, and Sharon S. Evans
- Subjects
0301 basic medicine ,Tumor microenvironment ,vasculature ,urogenital system ,business.industry ,Angiogenesis ,Cancer ,Review ,lymphocyte ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Immune system ,Oncology ,trafficking ,In vivo ,030220 oncology & carcinogenesis ,intravital microscopy ,medicine ,Cancer research ,Tumor-Associated Vasculature ,Personalized medicine ,business ,Intravital microscopy - Abstract
Intravital microscopy (IVM) is a dynamic imaging modality that allows for the real time observation of biologic processes in vivo, including angiogenesis and immune cell interactions. In the setting of preclinical cancer models, IVM has facilitated an understanding of the tumor associated vasculature and the role of effector immune cells in the tumor microenvironment. Novel approaches to apply IVM to human malignancies have thus far focused on cancer diagnosis and tumor vessel characterization, but have the potential to provide advances in the field of personalized medicine by identifying individual patients who may respond to systemically delivered chemotherapeutic drugs or immunotherapeutic agents. In this review, we highlight the role that IVM has had in investigating tumor vasculature and the tumor microenvironment in preclinical studies and discuss its current and future applications to directly observe human tumors.
- Published
- 2018
- Full Text
- View/download PDF
34. Ceramide species are elevated in human breast cancer and are associated with less aggressiveness
- Author
-
Junko Tsuchida, Kazuaki Takabe, Kazuki Moro, Emmanuel Gabriel, Tsutomu Kawaguchi, Li Yan, Qianya Qi, Toshifumi Wakai, and Masayuki Nagahashi
- Subjects
0301 basic medicine ,Ceramide ,03 medical and health sciences ,chemistry.chemical_compound ,breast cancer ,Breast cancer ,Gene expression ,medicine ,Clinical significance ,ceramide ,skin and connective tissue diseases ,Gene ,chemistry.chemical_classification ,business.industry ,medicine.disease ,Sphingolipid ,3. Good health ,030104 developmental biology ,Enzyme ,Oncology ,chemistry ,Cancer cell ,Cancer research ,prognosis ,sphingolipid ,business ,metabolism ,Research Paper - Abstract
Sphingolipids have emerged as key regulatory molecules in cancer cell survival and death. Although important roles of sphingolipids in breast cancer progression have been reported in experimental models, their roles in human patients are yet to be revealed. The aim of this study was to investigate the ceramide levels and its biosynthesis pathways in human breast cancer patients. Breast cancer, peri-tumor and normal breast tissue samples were collected from surgical specimens from a series of 44 patients with breast cancer. The amount of sphingolipid metabolites in the tissue were determined by mass spectrometry. The Cancer Genome Atlas was used to analyze gene expression related to the sphingolipid metabolism. Ceramide levels were higher in breast cancer tissue compared to both normal and peri-tumor breast tissue. Substrates and enzymes that generate ceramide were significantly increased in all three ceramide biosynthesis pathways in cancer. Further, higher levels of ceramide in breast cancer were associated with less aggressive cancer biology presented by Ki-67 index and nuclear grade of the cancer. Interestingly, patients with higher gene expressions of enzymes in the three major ceramide synthesis pathways showed significantly worse prognosis. This is the first study to reveal the clinical relevance of ceramide metabolism in breast cancer patients. We demonstrated that ceramide levels in breast cancer tissue were significantly higher than those in normal tissue, with activation of the three ceramide biosynthesis pathways. We also identified that ceramide levels have a significant association with aggressive phenotype and its enzymes have prognostic impact on breast cancer patients.
- Published
- 2018
- Full Text
- View/download PDF
35. Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer
- Author
-
Raed M. Alnaji, Hector R. Nava, Emmanuel Gabriel, Steven N. Hochwald, Moshim Kukar, Smit Singla, William Du, and Kristopher Attwood
- Subjects
medicine.medical_specialty ,business.industry ,Signet ring cell ,Proportional hazards model ,medicine.medical_treatment ,Significant difference ,Gastroenterology ,Improved survival ,Esophageal cancer ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Esophagectomy ,030220 oncology & carcinogenesis ,Patient performance ,Medicine ,Pathologic Response ,Original Article ,030211 gastroenterology & hepatology ,business - Abstract
Background: The relationship of complete pathologic response (cPR) with the timing of esophagectomy after neoadjuvant chemoradiation (nCRT) is not well defined. We sought to determine if a delay in esophagectomy after nCRT would result in increased likelihood of cPR and improved survival. Methods: This is a retrospective analysis of a prospectively maintained database of all patients treated with nCRT and esophagectomy between 2004 and 2014. Patients were divided into two groups based on timing of esophagectomy (≤50 vs. >50 days) after completion of nCRT. Survival outcomes were compared using standard Kaplan-Meier curves, and multivariable analyses were performed using Cox regression models. Results: This study included 226 patients (males, 211 and median age, 61 years) for analysis. Fifty-two patients (23%) in the early group (≤50 days) were compared to 174 patients (77%) in the delayed group (>50 days). The two groups were similar with respect to age, gender, comorbid conditions, ECOG status, location, grade, and tumor histology. There was no statistically significant difference in cPR rate between the early and late groups (26.9% vs. 19.0%, respectively, P=0.24). On multivariable analysis, lower age, absence of signet cell histology, better ECOG status, shorter length of stay and cPR were independent predictors of improved survival. The median follow-up was 52 months (range, 2–110 months), and there was no difference in the median overall survival (OS) between the early and late groups (48.9 vs. 42.6 months, respectively, P=0.73). Conclusions: This analysis of a large cohort of patients with esophageal cancer undergoing multi-modality therapy shows that cPR is independent of the timing of esophagectomy. Other considerations for the timing of surgery, including recovery from nCRT and patient performance, may have more relevant roles than cPR when deciding when to perform esophagectomy.
- Published
- 2018
- Full Text
- View/download PDF
36. Development of a Neu-Expressing Mouse Melanoma Cell Line to Be Used As a Model for Anti-HER2 Therapy in Melanoma
- Author
-
Catherine Mangum, Emmanuel Gabriel, Sanjay P. Bagaria, and Jamie Kaplan
- Subjects
business.industry ,Cell culture ,Melanoma ,Cancer research ,Medicine ,Surgery ,Anti her2 ,Mouse Melanoma ,business ,medicine.disease - Published
- 2021
- Full Text
- View/download PDF
37. The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer
- Author
-
Mira Shoukry, Jamie Kaplan, Sacha Broccard, and Emmanuel Gabriel
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,recurrence ,medicine.medical_treatment ,Review ,Disease ,chemotherapy ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,Internal medicine ,medicine ,Mammography ,Liquid biopsy ,RC254-282 ,circulating tumor DNA ,Chemotherapy ,liquid biopsy ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,030104 developmental biology ,Circulating tumor DNA ,030220 oncology & carcinogenesis ,Potential biomarkers ,business - Abstract
Simple Summary As breast cancer diagnoses continue to rise among women worldwide, it is important to explore and improve upon methods of diagnosis and surveillance. Liquid biopsies have the potential to become the forefront of such efforts, with circulating tumor DNA (ctDNA) increasingly being studied as a biomarker for breast cancer. This review aims to summarize the current applications of ctDNA in the diagnosis and surveillance of breast cancer. Additionally, comparisons between ctDNA and other currently utilized methods and biomarkers provide further insight into the emerging role of ctDNA for the management of breast cancer. Abstract With the incidence of breast cancer steadily rising, it is important to explore novel technologies that can allow for earlier detection of disease as well more a personalized and effective treatment approach. The concept of “liquid biopsies” and the data they provide have been increasingly studied in the recent decades. More specifically, circulating tumor DNA (ctDNA) has emerged as a potential biomarker for various cancers, including breast cancer. While methods such as mammography and tissue biopsies are the current standards for the detection and surveillance of breast cancer, ctDNA analysis has shown some promise. This review discusses the versatility of ctDNA by exploring its multiple emerging uses for the management of breast cancer. Its efficacy is also compared to current biomarkers and technologies.
- Published
- 2021
- Full Text
- View/download PDF
38. Conditional Survival-Based 'Abbreviated' Routine Cancer Surveillance for Pathologic Stage IB Melanoma
- Author
-
Rebecca May, Edward Cho, Joseph J. Skitzki, Michelle Lichtenthal, Moshim Kukar, Valerie Francescutti, Emmanuel Gabriel, John M. Kane, and Adrienne Groman
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,Every Six Months ,Sentinel lymph node ,Disease-Free Survival ,Tertiary Care Centers ,Breslow Thickness ,03 medical and health sciences ,0302 clinical medicine ,Biopsy ,Humans ,Medicine ,030212 general & internal medicine ,Melanoma ,Early Detection of Cancer ,Neoplasm Staging ,medicine.diagnostic_test ,Sentinel Lymph Node Biopsy ,business.industry ,Cancer ,Extremities ,General Medicine ,Middle Aged ,Thorax ,Prognosis ,medicine.disease ,Primary tumor ,Head and Neck Neoplasms ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Cohort ,Female ,Radiology ,Neoplasm Recurrence, Local ,business - Abstract
A negative sentinel lymph node biopsy (SLNB) for stage IB (T1b/T2a N0) melanoma would predict an excellent long-term prognosis. Combined with the concept of conditional survival, an “abbreviated” cancer surveillance strategy was implemented to reduce the number of visits and total length of follow-up. Retrospective review of all pathologic stage IB melanoma patients (negative SLNB) at a single institution between 2006 and 2008 after implementation of an “abbreviated” cancer surveillance; clinic visits every six months for five years followed by one annual visit (total follow-up six years). Patient demographics, tumor characteristics, and information regarding recurrences were obtained. Recurrence-free, disease-specific, and overall survival were calculated. Eighty-seven patients underwent the “abbreviated” cancer surveillance. Median age was 55.4 years and 50.6 per cent were male. Median Breslow thickness was 1.1 mm (range 0.5–2.0 mm) and 1.1 per cent were ulcerated. Primary tumor site was 49 per cent extremities, 39 per cent trunk, and 12 per cent head/ neck. Median follow-up was 68.6 months. Five-year recurrence-free, disease-specific, and overall survivals were 89, 95, and 88 per cent, respectively. During surveillance, 10 patients had concerning symptoms or physical findings prompting subsequent workup, all of which were negative for recurrence/metastases. There were only three true melanoma recurrences; all were distant metastases and presented symptomatically between scheduled follow-up visits. In light of the excellent prognosis for pathologic (SLNB negative) stage IB melanoma, an “abbreviated” cancer surveillance schedule based on conditional survival would reduce both direct and indirect costs in this cohort. The few recurrences were symptomatic and unlikely to have changed with more intensive surveillance.
- Published
- 2017
- Full Text
- View/download PDF
39. Novel mouse models of hepatic artery infusion
- Author
-
Minhyung Kim, Daniel T. Fisher, Joseph J. Skitzki, Emmanuel Gabriel, Andrei V. Gudkov, Alexis M. Korman, Colin A. Powers, and Sandra Sexton
- Subjects
medicine.medical_specialty ,Superior pancreaticoduodenal artery ,Portal venous system ,Antineoplastic Agents ,Gastroenterology ,Article ,Mice ,03 medical and health sciences ,First pass effect ,Hepatic Artery ,Liver Neoplasms, Experimental ,0302 clinical medicine ,Cell Line, Tumor ,medicine.artery ,Internal medicine ,Animals ,Infusions, Intra-Arterial ,Medicine ,Distribution (pharmacology) ,030212 general & internal medicine ,Mice, Inbred BALB C ,business.industry ,Liver Neoplasms ,Reproducibility of Results ,Mice, Inbred C57BL ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Toxicity ,Female ,Surgery ,Fluorouracil ,Radiology ,Liver function ,business ,Perfusion ,Artery - Abstract
BACKGROUND: The liver has unique anatomy in that most blood flow to normal hepatocytes is derived from the portal venous system, while liver tumors obtain their nutrient blood supply exclusively from the hepatic artery. The focused arterial delivery of anticancer agents to liver tumors has been performed for decades; however, preclinical models to standardize drug regimens and examine novel agents have been lacking. The purpose of this study was to establish preclinical hepatic artery infusion (HAI) models in a mouse, and to evaluate the safety and delivery capability of the models. MATERIAL AND METHODS: Female C57BL/6 and BALB/c mice aged 8–12 wk were used to develop models of HAI via the hepatic artery (HA), superior pancreaticoduodenal artery (SPDA), or lienogastric artery (LGA). Success rates, distribution of perfusion, and associated morbidity and mortality were analyzed between groups. RESULTS: All three models were feasible and reproducible in mice, and there was no statistical difference on body weight change between models. The HA model had a 13.3% mortality from acute liver failure, and the SPDA model demonstrated significant duodenal and pancreatic toxicity. SPDA and LGA routes had the highest success rates (96.7% and 91.4%, respectively) with low mortality, better drug delivery, and preserved physiologic liver function compared to the HA model. CONCLUSIONS: The optimal route of HAI was mouse breed-specific; SPDA access in BALB/c mice, and the LGA access in C57BL/6 mice. The described techniques serve as a reproducible platform for the identification and characterization of therapeutics for diverse metastatic liver tumors.
- Published
- 2017
- Full Text
- View/download PDF
40. Water lavage as an adjunct to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
- Author
-
Daniel T. Fisher, Emmanuel Gabriel, Kristopher Attwood, Minhyung Kim, Colin A. Powers, Anthony Visioni, Joseph J. Skitzki, and Smit Singla
- Subjects
Male ,Subset Analysis ,Hyperthermia ,medicine.medical_specialty ,medicine.medical_treatment ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,Gastrointestinal cancer ,Therapeutic Irrigation ,Peritoneal Neoplasms ,Retrospective Studies ,Chemotherapy ,business.industry ,Water ,Cancer ,Retrospective cohort study ,Cytoreduction Surgical Procedures ,Hyperthermia, Induced ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Chemotherapy, Cancer, Regional Perfusion ,030220 oncology & carcinogenesis ,Anesthesia ,Conventional PCI ,Female ,030211 gastroenterology & hepatology ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,business - Abstract
Background Water lavage (WL) during gastrointestinal cancer surgery has osmotically mediated lytic effects on tumor cells. We investigated the safety and efficacy of WL with CRS-HIPEC. Methods This is a retrospective review, 1/2003-7/2014, of a single institution experience with CRS-HIPEC comparing patients who had WL (WL+) to those who did not (WL−). Results Of 157 CRS-HIPECs, 16 (10.2%) were WL+. WL+ had more PCI scores >20 compared to WL− (56.3% vs 19.4%, respectively, p = 0.003); however, the completeness of cytoreduction (CC) was similar. There were no differences in hospital length of stay or post-operative complications. The average POD 1 sodium (Na) level was statistically lower in the WL+ group (133.6 ± 2.5 vs 135.5 ± 3.2 mEq/L, p = 0.023); however, the average Na at discharge for each group was 140 mEq/L. There were no differences in 3-year OS (3WL+:0.63 vs WL−:0.68, p = 0.97) or RFS (WL+:0.32 vs WL−:0.39, p = 0.47). A subset analysis for patients with PCI >20 showed no difference between groups. Conclusions WL offers a low cost, safe and theoretically efficacious method of tumor cell lysis for peritoneal malignancy.
- Published
- 2017
- Full Text
- View/download PDF
41. Gemcitabine and capecitabine for advanced biliary cancer
- Author
-
Steven N. Hochwald, Shipra Gandhi, Boris W. Kuvshinoff, Emmanuel Gabriel, Renuka Iyer, and Kristopher Attwood
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Neutropenia ,Gastroenterology ,Capecitabine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Adjuvant therapy ,Gallbladder cancer ,Chemotherapy ,business.industry ,Gallbladder ,medicine.disease ,Gemcitabine ,Regimen ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Original Article ,business ,medicine.drug - Abstract
Background: Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience. Methods: Single institution, retrospective study from 2005 to 2015 of ABC treated with gem-cap. Results: A total of 372 patients with ABC were identified, of whom 227 (61.0%) were treated with chemotherapy. 153 patients (67.4%) received gem-cap, of which 129 (56.8%) received it in the first line. Thirty two point six percent (42/129) were locally advanced, 67.4% (87/129) had metastatic disease, and 18.6% (24/129) received it as adjuvant therapy. Disease sites included 48.8% [63] intrahepatic cholangiocarcinoma (IHCC), 24.0% [31] extrahepatic cholangiocarcinoma (EHCC) and 27.1% [35] gallbladder carcinoma (GBC). Median follow-up was 49.7 months (mo). The median PFS and OS were 8.0 mo [95% confidence intervals (CI): 6.0–9.3] and 13.0 mo (95% CI: 10.7–17.4), respectively. Overall, 53.5% (69/129) experienced a grade 3/4 toxicity. The most common (35.7%) was a hematologic toxicity (neutropenia or thrombocytopenia) followed by infection (25.6%). Conclusions: Gem-cap provides similar survival outcomes to gemcitabine/cisplatin based on historical comparison to the ABC-2 trial (median PFS =8.0 mo and OS =11.7 mo). Gem-cap may offer the advantage of fewer adverse events compared to the levels reported in ABC-2 (grade 3/4 events 70.7%).
- Published
- 2017
- Full Text
- View/download PDF
42. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
- Author
-
Steven N. Hochwald, Emmanuel Gabriel, Boris W. Kuvshinoff, Steven J. Nurkin, Katherine T. Ostapoff, and Kristopher Attwood
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Time Factors ,Databases, Factual ,medicine.medical_treatment ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Article ,03 medical and health sciences ,Pancreatectomy ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Adjuvant therapy ,Carcinoma ,Humans ,030212 general & internal medicine ,Stage (cooking) ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Chemotherapy ,Chi-Square Distribution ,Hepatology ,business.industry ,Gastroenterology ,Chemoradiotherapy, Adjuvant ,Middle Aged ,medicine.disease ,United States ,Pancreatic Neoplasms ,Treatment Outcome ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Adenocarcinoma ,Female ,business ,Adjuvant ,Chemoradiotherapy ,Carcinoma, Pancreatic Ductal - Abstract
Current guidelines recommend adjuvant chemotherapy for resected pancreatic adenocarcinoma (PDAC). However, no studies have addressed its survival benefit for stage I patients as they comprise10% of PDAC.Using the NCDB 2006-2012, resected PDAC patients with stage I disease who received adjuvant therapy (chemotherapy or chemoradiation) were analyzed. Factors associated with overall survival (OS) were identified.3909 patients with resected stage IA or IB PDAC were identified. Median OS was 60.3 months (mo) for stage IA and 36.9 mo for IB. 45.5% received adjuvant chemotherapy; 19.9% received adjuvant chemoradiation. There was OS benefit for both stage IA/IB patients with adjuvant chemotherapy (HR = 0.73 and 0.76 for IA and IB, respectively, p = 0.002 and0.001). For patients with Stage IA disease (n = 1,477, 37.8%), age ≥70 (p 0.001), higher grade (p 0.001), ≤10 lymph nodes examined (p = 0.008), positive margins (p 0.001), and receipt of adjuvant chemoradiation (p = 0.002) were associated with worse OS. For stage IB patients (n = 2,432, 62.2%), similar associations were observed with the exception of adjuvant chemoradiation whereby there was no significant association (p = 0.35).Adjuvant chemotherapy was associated with an OS benefit for patients with stage I PDAC; adjuvant chemoradiation was either of no benefit or associated with worse OS.
- Published
- 2017
- Full Text
- View/download PDF
43. Disparities in the Age-Related Rates of Colorectal Cancer in the United States
- Author
-
Kristopher Attwood, Steven J. Nurkin, Patrick McKay Boland, Eisar Al-Sukhni, Katherine T. Ostapoff, and Emmanuel Gabriel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Black People ,Rectum ,Adenocarcinoma ,White People ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Epidemiology ,medicine ,Humans ,Socioeconomic status ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Rectal Neoplasms ,business.industry ,Incidence ,Incidence (epidemiology) ,Retrospective cohort study ,Hispanic or Latino ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,business - Abstract
The incidence of colorectal cancer (CRC) among Americans under the age of 50 years is increasing. The purpose of this study was to identify racial and socioeconomic disparities associated with this trend. The National Cancer Data Base was used to identify patients with CRC from 1998 to 2011. Patients were stratified by age (60 years), with ages 50 to 60 years omitted from the analysis to minimize overlapping trends between the two age groups. Relative frequencies (RFs) by year were plotted against demographic variables. Changes in RF over time and intervals from diagnosis to treatment (including surgery and chemotherapy) were compared. A total of 1,213,192 patients were studied; 885,510 patients with colon cancer and 327,682 with rectal or rectosigmoid cancer. Patients 60 years, with the highest rate of increase in stage III colon cancer (0.198% per year). Patients
- Published
- 2017
- Full Text
- View/download PDF
44. Papanicoleau Smear Usage and Prevalence of Premalignant Cervical Lesion among Women Living with HIV Attending a Federal Teaching Hospital in South-West Nigeria: A Comparative Study
- Author
-
Adebara Idowu Oluwaseyi, O.T. Elegbede, Segun Mathew Agboola, Shabi Om, Oluwaserimi Adewumi Ajetunmobi, Aishatu Omoragbon, and Olusegun Emmanuel Gabriel
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,General surgery ,prevalence ,Human immunodeficiency virus (HIV) ,Papanicoleau smear ,Cervical lesion ,medicine.disease_cause ,Teaching hospital ,HIV-positive women ,premalignant cervical lesions ,medicine ,business - Abstract
Aim: Cancer of the cervix is the third most common cancer among women worldwide, and in Nigeria it is the second most common female cancer. Infection with the Human immunodeficiency virus (HIV) is associated with an increased risk of prevalent, incident and persistent squamous intraepithelial lesions (SILs) of the cervix. The aim was to determine the level of awareness of cervical cancer screening test and the development of premalignant cervical lesions among HIV positive women. Study Design: A Hospital based comparative cross-sectional study. Place and Duration of the Study: The study was carried out in the HIV clinic and general outpatient clinic of Federal Teaching Hospital Ido-ekiti, Ekiti state Nigeria. It was carried out from July to September 2015. Methodology: The study was carried out among 65 HIV-positive and 65 HIV-negative women. Data were collected from the interviewees. Participants also had Pap smear. Data collected were analyzed using statistical package for social sciences version 19. Results: The mean age was 39.73 (±8.57) and 40.98 (±10.68) among the HIV positive and negative women respectively. Only 27.7% of the HIV-positive women compared to 56.9% of the HIV negative women had heard of cervical cancer with P= 0.001. The level of awareness of cervical cancer screening test was 15.4% and 50.8% among the HIV positive and negative women respectively (P= 0.001). The prevalence of premalignant cervical lesions among the study and control groups was 26.2% and 16.9% respectively. This showed that premalignant cervical lesion was more prevalent among HIV-positive women though not statistically significant (P=0.201). However, using risk ratio (RR), the risk of developing cervical lesions is 1.55 times more in HIV exposed women than HIV negative women. Conclusion: There is therefore need for the Physicians to use every opportunity to counsel their clients on the need for routine cervical cancer screening especially in adult HIV clinics.
- Published
- 2017
- Full Text
- View/download PDF
45. Metabolic Syndrome and Kidney Damage: Prevalence and Assessment of Risk among Apparently Healthy Resident of Ado Ekiti, South West Nigeria
- Author
-
Julius Gbenga Olaogun, Mojeed Rafiu, Daisi D. Ajayi, Emmanuel E. Eyitayo, Ayokunle S Dada, and Olusegun Emmanuel Gabriel
- Subjects
Kidney ,medicine.medical_specialty ,Traditional medicine ,business.industry ,Renal function ,General Medicine ,medicine.disease ,Obesity ,medicine.anatomical_structure ,Internal medicine ,Medicine ,Metabolic syndrome ,business ,Kidney disease - Published
- 2017
- Full Text
- View/download PDF
46. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study
- Author
-
Steven J. Nurkin, Kristopher Attwood, Emmanuel Gabriel, Eisar Al-Sukhni, Kazunori Kanehira, and Charles LeVea
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Pathology ,Multivariate analysis ,Lymphovascular invasion ,Colorectal cancer ,Perineural invasion ,Adenocarcinoma ,Perineum ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Biopsy ,Humans ,Medicine ,Neoplasm Invasiveness ,Lymph node ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Lymphovascular ,medicine.anatomical_structure ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,030211 gastroenterology & hepatology ,Surgery ,Endothelium, Vascular ,Colorectal Neoplasms ,business - Abstract
Background Lymphovascular and perineural invasion (LVI and PNI) are associated with poor outcomes in several cancers. We sought to identify clinical variables associated with LVI and PNI in colorectal cancer (CRC) and to determine their impact on survival. Methods A retrospective review was performed of the National Cancer Data Base (NCDB), 2004–2011. Patients with CRC and a documented LVI or PNI status were included. Multivariate analysis was conducted to examine the associations between clinical variables and LVI/PNI, PNI and survival, and LVI/PNI and lymph node (LN) status in patients with T1 and T2 tumors. Results In total, 158,777 patients were included. LVI status was documented for 139,026 patients, 26.3% of whom were positive. PNI status was documented in 142,034 patients, 11.1% of whom were positive. The multivariable model identified a number of pathologic and clinical characteristics associated with the presence of LVI and PNI, including a number of features of advanced CRC. PNI was independently associated with reduced survival (HR 3.55, 95%CI 1.78–7.09). In T1 or T2 tumors, LVI and PNI were significantly associated with LN involvement. Conclusions LVI and PNI are associated with advanced CRC. PNI is an independent poor prognostic marker for survival in CRC. LVI and PNI are associated with LN involvement in T1 and T2 tumors. Documentation of LVI and PNI status on biopsy specimens may help in prognostication and decision-making in the management of these early tumors.
- Published
- 2017
- Full Text
- View/download PDF
47. ASO Author Reflections: Does Overall Survival Benefit From Complete Pathologic Responders Vary With Treatment Approach?
- Author
-
Moshim Kukar, Emmanuel Gabriel, and Denslow A Trumbull
- Subjects
medicine.medical_specialty ,Cancer Survivors ,Oncology ,Surgical oncology ,business.industry ,Neoplasms ,General surgery ,Overall survival ,medicine ,MEDLINE ,Humans ,Surgery ,business - Published
- 2020
- Full Text
- View/download PDF
48. Socio-Demographic Disparities in Gastric Adenocarcinoma: A Population-Based Study
- Author
-
Riccardo Lemini, Chong Wang, Sarbajit Mukherjee, Rohit Gosain, Beas Siromoni, Navpreet Rana, Turab Mohammed, and Emmanuel Gabriel
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,outcomes ,lcsh:RC254-282 ,gastric ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Lymph node ,disparities ,adenocarcinoma ,business.industry ,Stomach ,Incidence (epidemiology) ,Univariate ,Cancer ,Retrospective cohort study ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,incidence ,Marital status ,Adenocarcinoma ,rural ,business ,urban ,stomach - Abstract
Background: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, accounting for 8.2% of cancer-related deaths. The purpose of this study was to investigate the geographic and sociodemographic disparities in gastric adenocarcinoma patients. Methods: We conducted a retrospective study in gastric adenocarcinoma patients between 2004 and 2013. Data were obtained from the National Cancer Data Base (NCDB). Univariate and multivariable analyses were performed to evaluate overall survival (OS). Socio-demographic factors, including the location of residence [metro area (MA) or rural area (RA)], gender, race, insurance status, and marital status, were analyzed. Results: A total of 88,246 [RA, N = 12,365, MA, N = 75,881] patients were included. Univariate and multivariable analysis showed that RA had worse OS (univariate HR = 1.08, p <, 0.01, multivariate HR = 1.04, p <, 0.01) compared to MA. When comparing different racial backgrounds, Native American and African American populations had poorer OS when compared to the white population, however, Asian patients had a better OS (multivariable HR = 0.68, p <, 0.01). From a quality of care standpoint, MA patients had fewer median days to surgery (28 vs. 33, 0.01) with fewer positive margins (6.3% vs. 6.9%, 0.01) when compared to RA patients. When comparing the extent of lymph node dissection, 19.6% of MA patients underwent an extensive dissection (more than or equal to 15 lymph nodes) in comparison to 18.7% patients in RA (p = 0.03). Discussion: This study identifies socio-demographic disparities in gastric adenocarcinoma. Future health policy initiatives should focus on equitable allocation of resources to improve the outcomes.
- Published
- 2019
49. Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA
- Author
-
Kristopher Attwood, Enrique F. Elli, Riccardo Lemini, Matthew S. Jorgensen, Sanjay P. Bagaria, Tariq Almerey, Emmanuel Gabriel, and Dorin T. Colibaseanu
- Subjects
Waiting time ,Male ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cancer ,General Medicine ,Health Status Disparities ,medicine.disease ,United States ,Race Factors ,Radiation therapy ,Treatment Outcome ,Oncology ,Asian People ,Stomach Neoplasms ,Internal medicine ,Patient experience ,Overall survival ,medicine ,Humans ,Female ,business ,Aged - Abstract
Background/aim We aimed to evaluate disparities in presentation and treatment of gastric cancer (GC), including time between diagnosis and treatment, based on race, focusing on Japanese patients within the USA. Patients and methods The National Cancer Database was queried for patients diagnosed with GC between 2004-2013. Clinical and treatment variables were summarized by race (White, non-Japanese Asian, Japanese). The association between race and overall survival (OS) was evaluated using the log-rank test. Results A total of 79,481 patients were included. Japanese patients received surgery the earliest after diagnosis in all stages. Regarding radiotherapy, white patients had the shortest waiting time followed by Asian and Japanese patients. Asian patients had better OS at both 3 and 5 years of follow-up. White patients were associated with the lowest OS. Conclusion Japanese and Asian GC patients have better OS compared to White patients. Moreover, there were disparities in time to both GC diagnosis and treatment, with Japanese patients being sooner diagnosed and surgically treated, which may ultimately impact patient experience.
- Published
- 2019
50. Prognostic Significance of Complete Pathologic Response Obtained with Chemotherapy Versus Chemoradiotherapy in Gastric Cancer
- Author
-
Denslow A Trumbull, Tamara Díaz Vico, Matthew S. Jorgensen, Kristopher Attwood, Emmanuel Gabriel, Riccardo Lemini, Maureen Brady, Moshim Kukar, and Wenyan Ji
- Subjects
Oncology ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Stomach Neoplasms ,Internal medicine ,parasitic diseases ,medicine ,Humans ,Stage (cooking) ,Survival rate ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,business.industry ,Proportional hazards model ,Cancer ,Chemoradiotherapy ,medicine.disease ,Prognosis ,Confidence interval ,Neoadjuvant Therapy ,Treatment Outcome ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
Few studies have compared the survival advantage of complete pathologic response (cPR) achieved through neoadjuvant chemotherapy (nCT) versus neoadjuvant chemoradiotherapy (nCRT) in gastric adenocarcinoma. Our study utilizes a large national cancer database to address this question. This is a retrospective review of patients with clinical stage I to III gastric adenocarcinoma from 2004 to 2013 who received nCT or nCRT. Patients who achieved cPR were selected. Associations were evaluated using Mann–Whitney U and Fisher’s exact tests. Survival information was summarized using standard Kaplan–Meier methods, where estimates of the median and 5-year survival rates were estimated with 95% confidence intervals. A total of 413 patients who had cPR were identified. Eighty-four patients received nCT and 329 patients received nCRT. Patients in the nCRT group had higher clinical stage (88.4% vs. 75.0%) and more proximal location of tumors (95.4% vs. 45.2%). The nCT group (n = 84) had a 94% 5-year survival rate, while the nCRT group’s (n = 329) rate was 60% (p
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.